XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 131 filers reported holding XENON PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37,576 | -99.3% | 11 | -100.0% | 0.01% | -99.4% |
| Q2 2023 | $5,216,212 | -9.2% | 135,486 | -15.6% | 0.83% | -36.2% |
| Q1 2023 | $5,743,793 | -9.2% | 160,486 | 0.0% | 1.30% | -14.7% |
| Q4 2022 | $6,327,963 | +9.2% | 160,486 | 0.0% | 1.53% | +32.2% |
| Q3 2022 | $5,794,000 | -20.4% | 160,486 | -33.0% | 1.16% | -13.0% |
| Q2 2022 | $7,283,000 | -0.5% | 239,441 | 0.0% | 1.33% | +37.9% |
| Q1 2022 | $7,320,000 | +30.8% | 239,441 | +33.7% | 0.96% | +15.5% |
| Q4 2021 | $5,597,000 | -68.3% | 179,138 | -84.5% | 0.83% | -32.9% |
| Q3 2021 | $17,635,000 | +15.5% | 1,154,138 | +40.8% | 1.24% | +0.6% |
| Q2 2021 | $15,262,000 | +7.8% | 819,706 | +3.7% | 1.23% | +159.2% |
| Q1 2021 | $14,154,000 | +312.4% | 790,676 | +254.3% | 0.48% | +215.2% |
| Q4 2020 | $3,432,000 | +38.9% | 223,173 | 0.0% | 0.15% | -15.6% |
| Q3 2020 | $2,470,000 | -33.9% | 223,173 | -25.2% | 0.18% | -39.9% |
| Q2 2020 | $3,739,000 | -25.7% | 298,173 | -32.8% | 0.30% | -21.2% |
| Q1 2020 | $5,030,000 | +57.6% | 443,582 | +82.2% | 0.38% | -26.9% |
| Q4 2019 | $3,192,000 | – | 243,470 | – | 0.52% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ghost Tree Capital, LLC | 850,000 | $15,215,000 | 3.58% |
| ACUTA CAPITAL PARTNERS, LLC | 412,500 | $7,384,000 | 2.66% |
| BVF INC/IL | 3,481,778 | $62,324,000 | 2.34% |
| Soleus Capital Management, L.P. | 708,117 | $12,675,000 | 2.28% |
| COMMODORE CAPITAL LP | 301,392 | $5,395,000 | 2.15% |
| DAFNA Capital Management LLC | 406,535 | $7,277,000 | 1.73% |
| Parkman Healthcare Partners LLC | 374,395 | $6,702,000 | 1.56% |
| Avoro Capital Advisors LLC | 3,650,000 | $65,335,000 | 1.13% |
| KNOTT DAVID M | 144,101 | $2,579,000 | 1.10% |
| Orbimed Advisors | 2,497,917 | $44,713,000 | 0.42% |